Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

2.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

3.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R.

Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188. doi: 10.1016/j.semcancer.2017.11.003. Epub 2017 Nov 6. Review.

4.

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.

Ramirez-Ardila D, Timmermans AM, Helmijr JA, Martens JWM, Berns EMJJ, Jansen MPHM.

Transl Oncol. 2017 Oct;10(5):854-866. doi: 10.1016/j.tranon.2017.08.002. Epub 2017 Sep 5.

5.

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

De Marchi T, Timmermans AM, Smid M, Look MP, Stingl C, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, van Deurzen CH, Luider TM, Foekens JA, Martens JW, Umar A.

Oncotarget. 2016 Jan 19;7(3):3098-110. doi: 10.18632/oncotarget.6521.

6.

Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.

van Roosmalen W, Le Dévédec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, Naffar-Abu-Amara S, Kirsanova C, Rustici G, Hoen PA, Martens JW, Foekens JA, Geiger B, van de Water B.

J Clin Invest. 2015 Apr;125(4):1648-64. doi: 10.1172/JCI74440. Epub 2015 Mar 16.

7.

Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.

van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.

Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.

PMID:
25522926
8.

High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.

Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW, Sleijfer S, Foekens JA, Berns PM, Jansen MP.

Ann Oncol. 2014 Nov;25(11):2185-90. doi: 10.1093/annonc/mdu391. Epub 2014 Sep 5.

PMID:
25193989
9.

Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.

Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A.

Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17.

10.

CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes.

Mostert B, Kraan J, Sieuwerts AM, van der Spoel P, Bolt-de Vries J, Prager-van der Smissen WJ, Smid M, Timmermans AM, Martens JW, Gratama JW, Foekens JA, Sleijfer S.

Cancer Lett. 2012 Jun 1;319(1):49-55. doi: 10.1016/j.canlet.2011.12.031. Epub 2011 Dec 24.

PMID:
22202642
11.

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146.

Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, Timmermans AM, Foekens R, Martens JW, Gratama JW, Foekens JA, Sleijfer S.

Breast Cancer Res Treat. 2011 May;127(1):33-41. doi: 10.1007/s10549-010-0879-y. Epub 2010 Apr 9.

PMID:
20379845
12.

Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.

Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolić L.

Mol Cell Proteomics. 2009 Jun;8(6):1278-94. doi: 10.1074/mcp.M800493-MCP200. Epub 2009 Mar 27.

14.

Immunocytochemical detection of prognostic markers in breast cancer; technical considerations.

Kuenen-Boumeester V, Timmermans AM, De Bruijn EM, Henzen-Logmans SC.

Cytopathology. 1999 Oct;10(5):308-16.

PMID:
10588349
15.

[Artificial rearing of young rats with rat's milk. Technic of milking and feeding].

Timmermans PJ, Timmermans AM.

Z Versuchstierkd. 1971;13(1):59-67. German. No abstract available.

PMID:
5112425
16.

Une microburette horizontale automatique perfectionnée.

LACOURT A, STOFFYN P, TIMMERMANS AM.

Mikrochemie. 1947 Jul;33(2-3):217-20. Undetermined Language. No abstract available.

PMID:
18921877
17.

L'étalonnage titrimétrique de microburettes capillaires.

LACOURT A, TIMMERMANS AM.

Bull Cl Sci Acad R Belg. 1947;32(1-3):52-62. Undetermined Language. No abstract available.

PMID:
20268267

Supplemental Content

Loading ...
Support Center